Abstract
NADH and FAD auto-fluorescence intensity and lifetime imaging are used to monitor breast cancer metabolism. In vivo imaging of xenograft tumors revealed metabolic differences in responsive but not resistant tumors treated with trastuzumab at earlier time points than FDG-PET.
© 2013 Optical Society of America
PDF Article | Presentation VideoMore Like This
Amy T. Shah, Alex J. Walsh, Paula R. Pohlmann, and Melissa C. Skala
FM4F.4 Frontiers in Optics (FiO) 2014
Melissa C. Skala, Alex J. Walsh, Amy T. Shah, Joseph T. Sharick, Tiffany M. Heaster, Rebecca S. Cook, Carlos L. Arteaga, Melinda E. Sanders, and Ingrid Meszoely
JW4A.1 Cancer Imaging and Therapy (Cancer) 2016
Alex Walsh, Rebecca S. Cook, Carlos L. Arteaga, and Melissa C. Skala
MT3C.3 Optical Molecular Probes, Imaging and Drug Delivery (OMP) 2013